|Bid||0.00 x 1000|
|Ask||0.00 x 2900|
|Day's Range||23.82 - 24.47|
|52 Week Range||10.94 - 27.79|
|PE Ratio (TTM)||3.55|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.93|
Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after the Trump administration released details on the latest round of China tariffs, to which China has responded in kind. In other news, the June Empire State Manufacturing Survey beat Wall Street expectations on nearly every front.
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a much debated social media play.
Cindy Eckert is the anti-Martin Shkreli — after the billion-dollar Valeant debacle, the founder of Sprout Pharmaceuticals is back as CEO and she's slashed the price of the little pink libido pill for women. Here's what she learned from the experience and where she goes from here.
Another quote used by Walsh, this one from Cindy Pearson of the National Women’s Health Network, claims that “Osteopenia is disease-mongering plain and simple.” Osteopenia is a term used to describe bone-thinning and is considered to be the mid-point between healthy bone and osteoporosis. Is osteopenia (bone-thinning) a disease?
NEW YORK , June 19, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company") (NYSE: VRX). ...
NEW YORK , June 19, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Valeant Pharmaceuticals International, Inc. ...
Shares of Valeant Pharmaceuticals International (VRX) started the week off on a down note, on news that the company received a Complete Response Letter from the Food and Drug Administration concerning its plaque psoriasis treatment Monday, and the shares are falling again today. Cantor Fitzgerald argued that the letter wasn't anything for investors to worry about, and today H.C. Wainwright analyst Raghuram Selvaraju argues much the same thing, even if he has a Neutral rating on the stock. Selvaraju writes that although the psoriasis drug, Duobrii, was one of the "Significant Seven" products around which he saw the "new" Valeant would be built, he--much like Cantor--hasn't included sales from the treatment in his model for 2018.
Valeant Pharmaceuticals International Inc.’s rebound from this year’s low in March was stopped in its tracks after U.S. regulators rejected its application for a plaque psoriasis lotion, Duobrii, that management saw as the first of many new drugs to hit the market in the next few years. Trading volume was more than 1.5 times the full-day average of the past three months as investors retreated even after the company pointed out that the Food and Drug Administration’s ruling was related to its pharmacokinetic data and said management is working to “resolve this matter expeditiously” and has already requested a meeting with regulators. Wells Fargo analyst David Maris warned that an approval may be delayed by six to nine months depending on Valeant’s need to generate additional data.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock took a hit on Monday after the U.S. Food and Drug Administration (FDA) rejected its psoriasis treatment. The Valeant Pharmaceuticals Intl Inc treatment that was rejected by the FDA is DUOBRII. This is a lotion made by the company’s Ortho Dermatologics division to treat plaque psoriasis.
Valeant Pharmaceuticals International Inc's plaque psoriasis treatment did not get approval from U.S. health regulators, a setback for the company which had high hopes for the lotion. A possible delay in approval of the treatment could be a blow to the company, as the treatment is one of the seven products, dubbed as the "Significant Seven", highlighted in Valeant's pipeline projected to raise over $1 billion over the next five years. "We wonder if Valeant will need to update this expectation for the 'Significant Seven' peak sales following the setback to Duobrii," Wells Fargo analyst David Maris said in a note.
Shares of Valeant Pharmaceuticals International (VRX) are lower on Monday, following news that the company received a Complete Response Letter from the Food and Drug Administration concerning its plaque psoriasis treatment. Chen writes that there are three reasons why she still has confidence in Valeant: The fact that the pharmacokinetic (PK) data has been available for "years," that in April, the Journal of American Academy of Dermatology published positive results from two Phase 3 randomized double-blind clinical trials for the first time, and sales of Duobrii wouldn't have been critical to Valeant's 2018 sales, given that it would have launched late in the year. Chen notes that the FDA's letter related to Duobrii's PK data, and Valeant is working with the agency.
Among the companies with shares expected to trade actively in Monday's session are Apple, Facebook, Alphabet, Comcast, General Electric and General Motors.
Valeant Pharmaceuticals International Inc. shares dropped 5.4% in premarket trade on Monday on news that the Food and Drug Administration failed to approve the company's lotion intended to treat plaque psoriasis. In a "complete response letter" notifying the company of the decision, the regulator noted questions about pharmacokinetic data, but did not specify problems with how well the product, Duobrii, works, nor with chemistry, manufacturing and controls processes, the company said. Valeant says it plans to work with the FDA to resolve the matter.
LAVAL, Quebec, June 18, 2018 /PRNewswire/ -- Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX), today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company's New Drug Application (NDA) for DUOBRII™1 (halobetasol propionate and tazarotene) (IDP-118) lotion in the treatment of plaque psoriasis. The CRL only noted questions regarding pharmacokinetic data," said Joseph C. Papa, chairman and CEO, Valeant. "We are working to resolve this matter expeditiously and have already requested a meeting with the FDA.
Now, Sprout Pharmaceuticals will make a second attempt to sell the drug but using a different method. Most importantly, Sprout will sell the drug for just $400, a 50% markdown from Valeant’s selling price. Both companies have an interest in getting patients prescribed on Addyi.
The U.S. government is shifting its focus from accusing drug companies of overcharging to encouraging the marketplace to operate more competitively. On May 31, FDA Commissioner Scott Gottlieb, announced a draft guidance that will limit drug companies in delaying generics to market. Previously, generics needed to negotiate with branded firms.
Now Available at Major U.S. Retailers LAVAL, Quebec , June 14, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International ...
It’s take two for Sprout Pharmaceuticals and Addyi, the only drug approved by the U.S. Food and Drug Administration to treat low sexual desire disorder (HSDD) in women.